• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Turnstone Biologics Corp.

    5/13/24 5:15:53 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TSBX alert in real time by email
    S-8 1 tsbx_s-8_2024.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on May 13, 2024

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    Turnstone Biologics Corp.

    (Exact name of registrant as specified in its charter)

    Delaware

    83-2909368

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

    9310 Athena Circle, Suite 300

    La Jolla, California

    92037

    (Address of principal executive offices)

    (Zip Code)

     

    Turnstone Biologics Corp. 2023 Equity Incentive Plan

    Turnstone Biologics Corp. 2023 Employee Stock Purchase Plan

    (Full titles of the plans)

    Sammy Farah, M.B.A., Ph.D.

    President and Chief Executive Officer

    Turnstone Biologics Corp.

    9310 Athena Circle, Suite 300

    La Jolla, California 92037

    (347) 897-5988

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Divakar Gupta

    Ryan Sansom

    Cooley LLP

    55 Hudson Yards

    New York, New York 10001

    (212) 479-6000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☒

     

     

     

     

     

     

     

    Emerging growth company

     

    ☒

     

     

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    EXPLANATORY NOTE

    REGISTRATION OF ADDITIONAL SHARES

    Pursuant to General Instruction E of Form S-8, Turnstone Biologics Corp. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) for the purpose of registering (i) 1,154,966 additional shares of its Common Stock under the 2023 Equity Incentive Plan (the “2023 Plan”), pursuant to the provisions of the 2023 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2023 Plan on January 1, 2024, and (ii) 230,993 additional shares of its Common Stock under the 2023 Employee Stock Purchase Plan (the “2023 ESPP,” together with the 2023 Plan, the “Plans”), pursuant to the provisions of the 2023 ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2023 ESPP on January 1, 2024. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

    The Registrant previously registered shares of its Common Stock for issuance under the Plans on a Registration Statement on Form S-8 filed with the Commission on July 25, 2023 (File No. 333-273421). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statement referenced above except as set forth below.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

    (a)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on May 13, 2024 (the “2023 Form 10-K”);

    (b)

    The information specifically incorporated by reference to our Annual Report from our Definitive Proxy Statement on Schedule 14A (File No. 001-41747), filed with the Commission on April 22, 2024;

    (c)

    The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed with the SEC on May 13, 2024;

    (d)

    The Registrant’s Current Report on Form 8-K filed with the SEC on April 16, 2024 (File No. 001-41747); and

    (e)

    The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed on July 17, 2023 (File No. 001-41747) under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.3 to the 2023 Form 10-K..

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

    Item 6. Indemnification of Directors and Officers.

    The Registrant is incorporated under the laws of the State of Delaware. Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit.

     


     

    Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and,in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

    As permitted by the Delaware General Corporation Law, the Registrant’s amended and restated certificate of incorporation and the Registrant’s amended and restated bylaws will provide that: (i) the Registrant is required to indemnify its directors to the fullest extent permitted by the Delaware General Corporation Law; (ii) the Registrant may, in its discretion, indemnify its officers, employees and agents as set forth in the Delaware General Corporation Law; (iii) the Registrant is required, upon satisfaction of certain conditions, to advance all expenses incurred by its directors in connection with certain legal proceedings; (iv) the rights conferred in the bylaws are not exclusive; and (v) the Registrant is authorized to enter into indemnification agreements with its directors, officers, employees and agents.

    The Registrant has entered into indemnification agreements with its directors and executive officers that require it to indemnify them against expenses, judgments, fines, settlements and other amounts that any such person becomes legally obligated to pay (including with respect to a derivative action) in connection with any proceeding, whether actual or threatened, to which such person may be made a party by reason of the fact that such person is or was a director or officer of the Registrant or any of its affiliates, provided such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the Registrant’s best interests.

    The Registrant maintains a directors’ and officers’ liability insurance policy. The policy insures directors and officers against indemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses the Registrant for those losses for which it has lawfully indemnified the directors and officers.

    Item 8. Exhibits.

    The exhibits to this Registration Statement are listed below:

     


     

    Exhibit

    Number

    Description

     

     

    4.1

    Amended and Restated Certificate of Incorporation, as currently in effect (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on July 25, 2023).

     

     

    4.2

    Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on July 25, 2023).

     

     

    4.3

    Form of Common Stock Certificate of the Registrant (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-272600), filed with the Commission on June 26, 2023).

     

     

    4.4

    Second Amended and Restated Investors’ Rights Agreement, by and among the Registrant and certain of its stockholders, dated June 29, 2021 (incorporated herein by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-272600), filed with the Commission on June 12, 2023).

     

     

    5.1*

    Opinion of Cooley LLP.

     

     

    23.1*

    Consent of Independent Registered Public Accounting Firm.

     

     

    23.2*

    Consent of Cooley LLP (included in Exhibit 5.1).

     

     

    24.1*

    Power of Attorney (included on the signature page).

     

     

    99.1

    The Registrant’s 2023 Equity Incentive Plan and Forms of Option Agreement and Exercise Notice thereunder (incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-272600), filed with the Commission on July 17, 2023).

     

     

    99.2

    The Registrant’s 2023 Employee Stock Purchase Plan of the Registrant (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-272600), filed with the Commission on July 17, 2023).

     

     

    107*

    Filing Fee Table.

    *

    Filed herewith.

     

     


     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Diego, California, on May 13, 2024.

     

     

     

    TURNSTONE BIOLOGICS CORP.

     

     

    By:

    /s/ Sammy Farah

     

    Sammy Farah, M.B.A., Ph.D.

     

    President and Chief Executive Officer and Director

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sammy Farah, M.B.A., Ph.D., and Venkat Ramanan, Ph.D., and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective on filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

    Title

    Date

    /s/ Sammy Farah

    Sammy Farah, M.B.A., Ph.D.

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

    May 13, 2024

    /s/ Venkat Ramanan

    Venkat Ramanan, Ph.D.

    Chief Financial Officer

    (Principal Financial Officer and Principal

    Accounting Officer)

    May 13, 2024

    /s/ Michael Burgess

    Michael Burgess, MBChB, Ph.D.

    Interim Chief Medical Officer and Director

    May 13, 2024

    /s/ Jerel Davis

    Jerel Davis, Ph.D.

    Director

    May 13, 2024

    /s/ Robert Gould

    Director

    May 13, 2024

    Robert Gould, Ph.D.

    /s/ Rishi Gupta

    Director

    May 13, 2024

    Rishi Gupta

    /s/ William D. Waddill

    William D. Waddill

    Director

    May 13, 2024

    /s/ Kanya Rajangam

    Kanya Rajangam, M.D., Ph.D.

    Director

    May 13, 2024

     

     

     


    Get the next $TSBX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TSBX

    DatePrice TargetRatingAnalyst
    2/5/2025$3.75 → $0.40Overweight → Neutral
    Piper Sandler
    11/15/2024Neutral → Underperform
    BofA Securities
    10/14/2024Buy → Neutral
    BofA Securities
    8/16/2023Market Perform
    SVB Securities
    8/15/2023$20.00Overweight
    Piper Sandler
    8/15/2023$18.00Buy
    BofA Securities
    More analyst ratings

    $TSBX
    SEC Filings

    View All

    SEC Form 15-12G filed by Turnstone Biologics Corp.

    15-12G - Turnstone Biologics Corp. (0001764974) (Filer)

    8/21/25 9:00:49 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Turnstone Biologics Corp.

    SCHEDULE 13D/A - Turnstone Biologics Corp. (0001764974) (Subject)

    8/12/25 4:44:49 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by Turnstone Biologics Corp.

    S-8 POS - Turnstone Biologics Corp. (0001764974) (Filer)

    8/11/25 4:50:28 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Orbimed Advisors Llc

    4 - Turnstone Biologics Corp. (0001764974) (Issuer)

    8/12/25 5:22:13 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Large owner Versant Ventures V, Llc

    4 - Turnstone Biologics Corp. (0001764974) (Issuer)

    8/12/25 4:34:57 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Jerel Davis

    4 - Turnstone Biologics Corp. (0001764974) (Issuer)

    8/8/25 4:06:58 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    Leadership Updates

    Live Leadership Updates

    View All

    Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

    SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. "We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies," said Sammy Farah, M.B.A., Ph.D., Turnstone's President and Chief Executive Officer. "The next frontier for TIL therapy is to extend its therapeutic activity

    5/13/24 5:01:26 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Turnstone Biologics Appoints William Waddill to its Board of Directors

    SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,

    4/16/24 9:00:00 AM ET
    $ANNX
    $ARWR
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

    Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported

    3/21/24 5:06:41 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Turnstone Biologics downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Turnstone Biologics from Overweight to Neutral and set a new price target of $0.40 from $3.75 previously

    2/5/25 8:04:09 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Turnstone Biologics downgraded by BofA Securities

    BofA Securities downgraded Turnstone Biologics from Neutral to Underperform

    11/15/24 8:23:44 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Turnstone Biologics downgraded by BofA Securities

    BofA Securities downgraded Turnstone Biologics from Buy to Neutral

    10/14/24 7:44:47 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

    - Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Turnstone Biologics Corp. (NASDAQ:TSBX) common stock for a price per share of $0.34 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Pr

    8/11/25 9:00:00 AM ET
    $TSBX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

    EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best

    6/27/25 7:30:00 AM ET
    $TSBX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights

    SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. Corporate Updates In January 2025, Turnstone made the determination to discontinue all TIDAL-01 clinical studies and halted further development of the program. As a result, the Company initiated a process to explore a range of potentia

    5/8/25 6:00:49 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    Financials

    Live finance-specific insights

    View All

    Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

    EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best

    6/27/25 7:30:00 AM ET
    $TSBX
    $XOMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

    SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer ("SITC") Annual Meeting. Turnstone also presented clinical data at t

    3/28/25 9:03:57 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TSBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

    SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

    5/31/24 4:23:52 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Turnstone Biologics Corp. (Amendment)

    SC 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)

    4/29/24 8:22:22 AM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Turnstone Biologics Corp.

    SC 13G - Turnstone Biologics Corp. (0001764974) (Subject)

    3/18/24 9:13:28 PM ET
    $TSBX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care